The management of borderline tumours of the ovary

Current Opinion in Oncology

Volumn 18, Issue 5, 2006, Pages 488-493

  Cadron, Isabelle ^a   Amant, Frederic ^a   Van Gorp, Toon ^a   Neven, Patrick ^a   Leunen, Karin ^a   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Borderline ovarian tumour; Management; Surgery

Indexed keywords

DNA;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; APPENDECTOMY; BIOPSY; CANCER RECURRENCE; CANCER SURVIVAL; CONCEPTION; CONSERVATIVE TREATMENT; HUMAN; LAPAROSCOPY; LAPAROTOMY; MANAGEMENT; OMENTECTOMY; OVARY TUMOR; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; REVIEW; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE;

CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 33746925218     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000239889.98289.ce     Document Type: Review

References (38)

1. Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006; 100:185-191. This article gives a good overview of concerns regarding conservative management for BOTs.
2. Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002; 16:513-527.
3. Sherman ME, Mink PJ, Curtis R, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma. A population-based analysis. Cancer 2004; 100:1045-1052.
4. Webb PM, Purdie DM, Grover S, et al. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004; 92:232-239.
5. Menzin AW, Gal D, Lovecchio JL. Contemporary surgical management of borderline ovarian tumors: a survey of the society of gynecologic oncologists. Gynecol Oncol 2000; 78:7-9.
6. Fauvet R, Boccara J, Dufournet C, et al. Laparoscopic management of borderline ovarian tumors: result of a French multicenter study. Ann Oncol 2005; 16:403-410. A large retrospective analysis of 358 patients with BOTs, with comparison of the mode of surgery and its relation to completeness of staging, cyst rupture and recurrence rates.
7. Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors. Result of a French multicenter study. Cancer 2004; 100:1145-1151.
8. Lin PS, Gershenson DM, Bevers MW, et al. The current status of surgical staging of ovarian serous borderline tumours. Cancer 1999; 85:905-911.
9. Camatte S, Morice P, Thoury A, et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 2004; 40:1842-1849.
10. Desfeux P, Camatte S, Hotelier G, et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumours. Gynecol Oncol 2005; 98:390-395. This is a large, retrospective study where laparoscopy and laparotomy for BOTs were compared for stage I disease.
11. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31:539-557.
12. Sherman ME, Beman J, Birrer MJ, et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol 2004; 35:961-970.
13. Morice P, Camatte S, Wicart-Poque F, et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update 2003; 9:185-192.
14. Silva EG, Tornos C, Zhuang Z, et al. Tumour recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol 1998; 17:387-389.
15. Morice P, Camatte S, Hassan JE, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75:92-96.
16. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19:2658-2664.
17. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99:3-10.
18. Kehoe S, Powell J. Long-term follow-up of women with borderline ovarian tumors. Int J Gynecol Obstet 1996; 53:139-143.
19. Camatte S, Rouzier R, Boccara-Dekeyser J, et al. Prognosis and fertility outcome after conservative treatment for borderline ovarian cancer: review of 68 cases [in French]. Gynecol Obset Fertil 2002; 30:583-591.
20. Ji H, Yliskoski M, Anttila M, et al. Management of stage I borderline ovarian tumors. Int J Gynecol Obstet 1996; 54:37-44.
21. Seracchioli R, Venturoli S, Colombo FM, et al. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early stage borderline ovarian tumors. Fertil Steril 2001; 76:999-1004.
22. Beiner ME, Gotlieb WH, Davidson B, et al. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001; 92:320-325.
23. Zanetta G, Rota S, Lissoni A. Ultrasound, physical examination and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol 2001; 81:63-66.
24. Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003; 79:1216-1221.
25. Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003; 14:592-598.
26. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357:176-182.
27. Maneo A, Vignali M, Chiari S, et al. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 2004; 94:387-392.
28. Deffieux X, Morice P, Camatte S, et al. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol 2005; 97:84-89.
29. Camatte S, Morice P, Atallah D, et al. Clinical outcome after laparoscopic pure management of borderline ovarian tumors: results of a series of 34 patients. Ann Oncol 2004; 15:605-609.
30. Vandenput I, Amant F, Vergote I. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy. Gynecol Oncol 2005; 98:523-524. This article debates the surgical approach for BOTs.
31. Tropé C, Kaern J, Vergote I, et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 53:236-243.
32. Kaern J, Tropé CG, Kristensen GB, et al. DNA ploidy; the most important prognostic factor in patients with borderline tumours of the ovary. Int J Gynaecol Cancer 1993; 3:349-358.
33. Le-Ming S, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11: 7273-7279. This review summarizes recent molecular studies of BOTs with emphasis on the role of serous BOTs in tumour progression and relation to invasive serous ovarian carcinoma.
34. Prat J, de Nictolis M. Serous borderline tumors of the ovary. A long term follow up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surgical Pathol 2002; 26:1111-1128.
35. Eichhorn JH, Bell DA, Young RH, Scully RE. Ovarian serous borderline tumors with micropapillary and cribi form patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999; 23:397-409.
36. Gotlieb WH, Flikke S, Davidson B, et al. Borderline tumors of the ovary. Fertility treatment, conservative management and pregnancy outcome. Cancer 1998; 82:141-146.
37. Papadimitriou DS, Martin-Hirsch P, Kitchener HC, et al. Recurrent borderline ovarian tumours after conservative management in women wishing to retain their fertility. Eur J Gynaecol Oncol 1999; 2:94-97.
38. Kurman RJ, Seidman JD, Shih I-M. Serous borderline tumours of the ovary. Expert opinion. Histopathology 2005; 47:310-318. This article discusses the classification of serous BOTs, their relation to ovarian cancer and the histopathological features in relation to their clinical significance.